ENDPOINTS

Insilico nabs $110M Series E for AI drug discovery after stalling Hong Kong IPO plans

Insilico Medicine, part of the first wave of AI-driven drug discovery and development shops, secured a $110 million megaround at a unicorn valuation for its pipeline of 30 treatment candidates. The clinical-stage startup raised more ...

Mar 12, 2025 - 14:51
 0
Insilico nabs $110M Series E for AI drug discovery after stalling Hong Kong IPO plans
Insilico Medicine, part of the first wave of AI-driven drug discovery and development shops, secured a $110 million megaround at a unicorn valuation for its pipeline of 30 treatment candidates. The clinical-stage startup raised more ...
Read More

Tags:

Previous Article

Viking Therapeutics taps CordenPharma to manufacture its obesity drugs

Next Article

In This Storied Egyptian City, Rising Seas are Causing Buildings to Crumble

Related Posts

Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharma

Decade after $8B deal, Roche offloads InterMune to myst...

Feb 10, 2025  0

CHMP recommends Regeneron, Novartis drugs that still await FDA approval

CHMP recommends Regeneron, Novartis drugs that still aw...

Feb 28, 2025  0

Sofinnova Partners raises €1.2B to invest in life sciences

Sofinnova Partners raises €1.2B to invest in life sciences

Mar 4, 2025  0